


Administration via CED

Trabedersen is administered via a method defined as convection-enhanced delivery (CED), using a system, which delivers the drug directly into the brain tumor (Figure 1). This means that the drug is targeted to the exact site of the tumor, preventing the need for it to travel from the rest of the body through the brain's protective barrier, known as the "blood-brain barrier". Patients participating in the SAPPHIRE study, who receive trabedersen therapy, will undergo minimal surgery to have the drug delivery system fitted.

Figure 1. Components of the trabedersen drug delivery system and surgical procedure

- **External parts (1, 2):** The **portable infusion pump (1)** contains trabedersen in a reservoir. The pump is connected to an **infusion line (2)**, which is connected to the **port chamber (3)**.
- **Implanted parts (3–5):** The **port chamber (3)** is implanted in the frontal part of the chest wall and connected to the **port catheter and the intratumoral catheter (4)**. The catheters are directed under the skin and end in the **brain tumor (5)**.



The drug delivery system includes a portable pump, which you can wear attached to a belt around your hip, allowing you to move around freely. This means you will only have to return to the hospital once a week, and you can pursue your daily activities. The maximum length of the treatment with trabedersen is 21 weeks.